In this issue:
ANO2-specific T-cells & EBNA-1 in MS
AI redefines MS as a disease continuum
Diagnostic role of PRLs at first clinical presentation
Secondary autoimmunity after immune reconstitution therapies in MS
Lifestyle factors in benign/non-benign MS
Frequency of critical demyelinating lesions in progressive MS
Finite-course ocrelizumab vs.standard-interval dosing in relapsing MS
DMTs in late-onset MS
Case report: tenofovir alafenamide fumarate in PML
Myelin injury in pre-symptomatic MS
Please login below to download this issue (PDF)